Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
Knowledge of the vital role of adenosine deaminase in lymphatic tissues has led to the development of enzyme inhibitors for treatment of lymphoid neoplasms. Deoxycoformycin is a potent ADA inhibitor and has been shown to be active in acute lymphoblastic leukemia at high doses but associated with unpredictable toxicity. In indolent lymphocytic leukemia or lymphoma with low ADA concentrations, this drug is effective at low doses with mild toxicity. The on-going EORTC trial shows that pentostatin is highly effective in hairy cell leukemia and can achieve durable complete remissions even if interferon alpha has failed. It will probably play an important role in the treatment of prolymphocytic leukemia, T- and B-cell chronic lymphocytic leukemia and Sézary syndrome.
Ho
A D
AD
Thaler
J
J
Willemze
R
R
Lauria
F
F
Derossi
G
G
Kuse
R
R
Stryckmans
P
P
Blanc
C M
CM
Cataldo
F
F
McVie
G
G
D000241:Adenosine / Q000378:metabolism; D058892:Adenosine Deaminase Inhibitors; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D004273:DNA, Neoplasm / Q000378:metabolism; D004341:Drug Evaluation; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D015649:Pentostatin; D012263:Ribonucleosides / Q000627:therapeutic use*; D012751:Sezary Syndrome / Q000188:drug therapy*
D058892:Adenosine Deaminase Inhibitors; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D012263:Ribonucleosides; D003070:Coformycin; D015649:Pentostatin; D000241:Adenosine